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Abstract
Background: Interleukin-22 (IL-22) is involved in lung diseases such as pneumonia, asthma and lung cancer. Lavage
mirrors the local environment, and may provide insights into the presence and role of IL-22 in patients.
Methods: Bronchoscopic lavage (BL) samples (n = 195, including bronchoalveolar lavage and bronchial washings)
were analysed for IL-22 using an enzyme-linked immunosorbent assay. Clinical characteristics and parameters from
lavage and serum were correlated with lavage IL-22 concentrations.
Results: IL-22 was higher in lavage from patients with lung disease than in controls (38.0 vs 15.3 pg/ml, p < 0.001).
Patients with pneumonia and lung cancer had the highest concentrations (48.9 and 33.0 pg/ml, p = 0.009 and
p < 0.001, respectively). IL-22 concentration did not correlate with systemic inflammation. IL-22 concentrations
did not relate to any of the analysed cell types in BL indicating a potential mixed contribution of different cell
populations to IL-22 production.
Conclusions: Lavage IL-22 concentrations are high in patients with lung cancer but do not correlate with systemic
inflammation, thus suggesting that lavage IL-22 may be related to the underlying malignancy. Our results
suggest that lavage may represent a distinct compartment where the role of IL-22 in thoracic malignancies
can be studied.
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Background
Interleukin-22 (IL-22) is a cytokine from the interleukin-
10 family which acts exclusively on IL22-receptor-1
(IL-22-R1) positive epithelial and endothelial cells [1].
In the lung IL-22 has been shown to be expressed by
T cells, natural killer-cells, macrophages, epithelial
and potentially also by tumour cells [2]. Its effects
can be both immunoregulatory and proinflammatory
depending on the stage of disease [3, 4]. IL-22 seems
to be protective in the acute phases of lung inflam-
mation or injury such as pneumonia, fungal infection,
traumatic lung injury, acute lung injury associated
with pancreatitis or the initial phase of allergic airway
inflammation [4–8]. In acute inflammation, IL-22 re-
cruits inflammatory cells to clear the infection, prob-
ably through the local upregulation of chemokines in
the lung, and to rescue lung epithelial cells from cell
death [5, 9]. However, if the pathological condition is
not cleared and the inflammation becomes chronic,
IL-22 seems to sustain inflammation and contribute
to the disease phenotype [3, 10]. Recently, we and
others have found evidence for IL-22 as a mediator in
the interaction between lung cancer cells and the im-
mune environment [11]. In vitro IL-22 promotes tumour
growth and chemotherapy resistance of lung cancer cells.
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Analysis of a large cohort of patients suffering from lung
cancer has revealed that IL-22 is frequently expressed in
lung cancer tissue, but the clinical significance of these
findings has yet to be addressed [12]. In addition, we pre-
viously measured IL-22 serum levels in lung cancer pa-
tients and matched healthy controls but did not find any
difference in spite of strong tissue expression [12]. These
observations prompted us to hypothesise that the systemic
circulation may not adequately reflect processes in the
lung, and that a closer analysis of the pulmonary compart-
ment may help to better understand the role of IL-22 in
lung cancer.
In the present study, we analysed lavage specimens
from 195 consecutive patients (37 with lung cancer)
undergoing clinically indicated bronchoscopy and corre-
lated IL-22 expression with local and systemic cell
counts and with serum markers of inflammation.
Methods
Study protocol
Patients underwent routine diagnostic or therapeutic
flexible bronchoscopy in the Respiratory Medicine and
Thoracic Oncology Section of the Internal Medicine
Department V, Ludwig Maximilians University of Munich,
Germany. Bronchoscopy was carried out under conscious
sedation following written informed consent. Bronchoal-
veolar lavage and bronchial washings, described here to-
gether as bronchoscopic lavage (BL), were carried out as
indicated, in most cases for diagnostic cytological, patho-
logical or microbiological evaluation. The decision to per-
form bronchoalveolar lavage vs. washings was at the
discretion of the responsible physician. Excess lavage ma-
terial was used for IL-22 analysis. Patient samples and data
were anonymised. Technicians performing the analyses
were blinded to all clinical information including patient
diagnosis. The study and its protocol were approved by
the local ethics board (Ethikkommission der Universität
München, decision number EK 376-11).
Patients and samples
Samples (166 bronchoalveolar lavages and 29 bronchial
washings) were collected from 195 patients comprising
83 women and 111 men (one gender not documented),
mean age 58.7 years. Patient characteristics are summa-
rized in Table 1. The diagnostic evaluation including
bronchoscopy and appropriate imaging, blood work,
biopsies and cultures as indicated revealed 47 patients
(24 %) with pulmonary infection, of whom three had
tuberculosis, two had pneumocystis jirovecii and 42 had
other bacterial and viral pneumonias. Thirty-seven pa-
tients (19 %) had a diagnosis of lung cancer, with 35
cases of non-small-cell lung cancer and two of small
cell lung cancer. Fourteen patients (7 %) had other thor-
acic malignancies or pulmonary metastases from
extrathoracic tumours. Diagnostic work-up revealed 79
patients with other lung diseases (41 %), including three
patients with Wegener’s granulomatosis, two patient with
chronic graft rejection following lung transplantation, two
patients with ARDS, four patients with exogenous allergic
alveolitis/hypersensitivity pneumonitis, 20 patients with
sarcoidosis and 43 patients with other interstitial lung dis-
eases or fibrosis. Twenty-two patients (11 %) who under-
went bronchoscopy due to pulmonary symptoms or
suspicion of malignancy on imaging were not diagnosed
with a pulmonary disorder following bronchoscopy and
clinical work up including appropriate imaging and pul-
monary function testing. These patients were used in the
analyses as the reference cohort. Because we did not re-
cruit healthy asymptomatic volunteers for bronchoscopy
and lavage the reference cohort includes individuals with
findings such as benign pulmonary nodules and/or prom-
inent mediastinal lymph nodes, and symptoms such as
cough due to vocal cord dysfunction.
Lavage samples and routine analysis
Bronchoalveolar lavage and bronchial washings were
collected and analysed according to standard operating
procedures at our centre, which are reviewed regularly
and are in line with published protocols [13] and indica-
tions [14, 15]. In brief, following local anesthesia patients
were sedated and intubated nasally with a flexible bron-
choscope. For bronchoalveolar lavage the bronchoscope
was advanced into wedge position preferentially in the
right middle lobe. Normal saline was instilled in 20 ml
aliquots to a total volume of 120 to 160 ml and was re-
trieved using suction. For bronchial washings the bron-
choscope was introduced into the area of clinical
interest (in most cases the segment thought to be
Table 1 Lavage interleukin-22 concentration in clinically char-
acterized cohorts
Characteristics Number of patients







Female 83 (44 %) 28 65
Male 111 (57 %) 37 82
Age (years) 58.7
Diagnosis
Pulmonary Infection 49 (25 %) 49 37
Lung Cancer 37 (19 %) 38 23
Thoracic manisfestation
of non-lung cancer
14 (7 %) 33 9
Other lung diseases 79 (41 %) 49 60
Reference cohort 22 (11 %) 15 12
DL detection limit of the assay
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affected by infection or tumour) and normal saline
(generally 40 to 80 ml) was instilled and retrieved
using suction. A standard morphological and im-
munologic analysis of BAL cellular components was
performed and included total cell count, differential
count of macrophages, lymphocytes and neutrophils
as well as flow cytometry analysis of the lymphocyte
subsets, including BAL CD4/CD8 T-cell ratio. Differ-
ential cell count (leukocytes, lymphocytes, neutrophils,
macrophages and CD4/CD8 ratio) subgroups were
based on accepted cut-off values used for the inter-
pretation of BAL fluid. Bacterial cultures and cyto-
logical analyses were performed as clinically indicated
at institutes affiliated with the Ludwig-Maximilians
Universität in Munich. Analysis of blood samples was
performed as part of the routine diagnostic work up
at the discretion of the treating physician and in line
with national recommendations [16].
Enzyme-linked immunosorbent assay (ELISA)
ELISA for IL-22 detection was obtained from R&D,
Abington, UK. In brief, 50 μl of diluted samples (in trip-
licates) were loaded and incubated for 2 h at room
temperature (RT). Detection antibody was applied for
2 h at RT and streptavidin-bound horseradish peroxidase
(HRP) was added for 20 min at RT. Absorption was
measured at 450 nm using a Mithras reader (Berthold
Technologies, Bad Wildbad, Germany). The detection
limit of the ELISA was 15 pg/ml.
Statistics and data analysis
For the IL-22 levels, mean values of three independ-
ent experiments each performed in triplicates were
calculated and used for subsequent analysis. The dif-
ferences in IL-22 levels between two independent
groups were assessed using the two-part Wilcoxon
test [17], in which the values below the detection
threshold 15 were set to 0. Similarly, correlations be-
tween IL-22 levels and other continuous variables
(CRP, leucocytes, lymphocytes, neutrophiles, macro-
phages, eosinophiles, CD4/CD8) were assessed using
Spearman’s rank-based correlation test with values of
Interleukin-22 below 15 set to 0. P-values < 0.05 were
considered as significant. Statistical analyses were per-
formed using R 3.0.2.
Samples from patients with lung cancer suffering
from chronic obstructive pulmonary disease (COPD)
or lung infection were excluded from the compara-
tive analysis with the control cohort and correlation
with clinical parameters to avoid bias in the IL-22
concentrations due to causes other than lung cancer
(n = 16, 45 %).
Results
IL-22 is elevated in bronchoscopic lavage from patients
with lung cancer
Patients with confirmed lung disease (n = 173) had
significantly higher IL-22 levels in bronchoscopic
lavage (BL) than the reference cohort (38 vs 15 pg/ml,
p < 0.001, Fig. 1a). The detailed characteristics of the
whole cohort are found in Table 1. We could not find any
correlation between IL-22 in BL and gender. IL-22 con-
centrations were higher in patients with pneumonia than
in controls (49 vs 15 pg/ml, p < 0.001 Fig. 1b). As IL-22 is
known to be elevated by acute or chronic inflammation,
as seen in pneumonia, we excluded patients with known
inflammatory lung diseases from the group of lung cancer
patients for further analysis. Patients with lung cancer had
high levels of IL-22 compared to the reference cohort
(33 vs 15 pg/ml, p = 0.009 Fig. 1c). We then extended
the cohort to patients with thoracic manifestations of
other malignancies, and found that IL-22 concentra-
tions were still elevated compared to controls (33 vs
15 pg/ml, p = 0.002, Fig. 1d).
IL-22 does not correlate with systemic inflammation
To investigate whether IL-22 is a marker of lung disease
and especially of lung cancer or rather a reflection of
systemic inflammation, we next analysed the relationship
between IL-22 and systemic parameters of inflammation.
In patients with lung cancer, we were unable to find a
relationship between IL-22 levels, systemic leukocyte,
lymphocyte or neutrophil counts and CRP (Table 2, c, e,
g, p = 0.19, 0.33, 0.28 and 0.35, respectively). We also in-
vestigated potential differences in IL-22 biology in the
largest disease subgroup (pneumonia) by investigating
possible correlations with IL-22 in BL from these pa-
tients. We did not find any evidence of a link between
IL-22 and systemic inflammation in pneumonia. No cor-
relation was found between IL-22 in BL of patients with
pneumonia and systemic leukocyte, lymphocyte or neu-
trophil counts and CRP (Table 2, p = 0.16, 0.21, 0.77 and
0.3, respectively). These results support the notion that
IL-22 in BL of lung cancer does not reflect systemic in-
flammation. However, the power of these correlation
analyses was moderate to low due to the limited size of
the groups, in particular for parameters with large pro-
portions of missing values.
IL-22 is not associated with a particular cell type in lavage
from patients with lung cancer or pneumonia
To identify potential sources of IL-22 within the lung
compartment resulting in elevated IL-22 levels, we cor-
related IL-22 levels with the measured cellular popula-
tions found in lavage. In lung cancer patients, we found
no correlation between IL-22 total percentages of lym-
phocytes, macrophages, neutrophils, eosinophils or the
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CD4 to CD8 T cell ratio (Table 3; p = 0.66, 0.59, 0.53,
0.95, 0.051, respectively). In lavage from patients with
pneumonia, IL-22 concentrations were unrelated to
total percentages of lymphocytes, macrophages, neu-
trophils, eosinophils and to the CD4 to CD8 T cell
ratio (Table 3, p = 0.5, 0.98, 0.86, 0.98, 0.65, respectively).
These results may indicate that IL-22 does not originate
Table 2 Correlation of IL-22 concentrations in lavage with systemic
inflammation parameters in samples from patients with pneumonia
or lung cancer. Leucocyte subpopulations were not measured in all
patients. Correlation was analyzed using Spearman’s rank-based
correlation test after setting all IL-22 values <15 to 0
Correlation of IL-22 in lavage with





Patients with Lung Cancer
Correlation of IL-22 in BL with CRP 16 0.19
Correlation of IL-22 in BL with Leucocytes 16 0.33
Correlation of IL-22 in BL with Lymphocytes 6 0.28
Correlation of IL-22 in BL with Neutrophils 6 0.35
Patients with Pneumonia
Correlation of IL-22 in BL with CRP 30 0.16
Correlation of IL-22 in BL with Leucocytes 30 0.21
Correlation of IL-22 in BL with Lymphocytes 18 0.77
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Fig. 1 IL-22 concentrations in lavage are higher in patients with lung cancer. a Comparison between BL IL-22 concentrations found in n = 173
bronchoscopic lavage (BL) samples from patients with lung disease and controls (n = 22). b Comparison between BL IL-22 concentrations for
samples from patients with pneumonia (n = 47) and controls (n = 22). c Comparison between BL IL-22 concentrations of patients with lung cancer
(n = 20) and controls (n = 22). Samples from lung cancer patients with a known coexisting inflammatory lung pathology such as COPD or lung
infection were excluded from this analysis to avoid confounding due to additional inflammation. d Comparison between BL IL-22 concentrations
for samples from patients with lung cancer and thoracic manifestations of other malignancies, summed up as “cancer” (n = 34) and controls
(n = 22). P-values were calculated using the two-part Wilcoxon test after setting all values <15 to 0
Table 3 Correlation of IL-22 concentrations in lavage with
distinct cell populations in the lavage samples of patients with
pneumonia or lung cancer. Not all lavage cell populations were
measured in all patients. Correlation was analyzed using
Spearman’s rank-based correlation test after setting all IL-22
values <15 to 0
Correlation of IL-22 in lavage





Patients with Lung Cancer
Correlation of IL-22 in BL with BL Lymphocytes 9 0.66
Correlation of IL-22 in BL with BL Macrophages 9 0.59
Correlation of IL-22 in BL with BL Neutrophils 9 0.53
Correlation of IL-22 in BL with BL Eosinophils 9 0.95
Correlation of IL-22 in BL with BL CD4/CD8 ratio 4 0.051
Patients with Pneumonia
Correlation of IL-22 in BL with BL Lymphocytes 32 0.5
Correlation of IL-22 in BL with BL Macrophages 32 0.98
Correlation of IL-22 in BL with BL Neutrophils 26 0.86
Correlation of IL-22 in BL with Eosinophils 26 0.98
Correlation of IL-22 in BL with BL CD4/CD8 ratio 34 0.65
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from a single cell population, should, however, be
interpreted with caution due to the limited size of the
subgroups.
Discussion
The present study demonstrates that IL-22 concentra-
tion in pulmonary lavage samples can be quantified
using ELISA and that the levels of IL-22 in lavage vary
between different disease entities. Patients with bacterial
pneumonia, lung cancer or pulmonary manifestations of
other tumours appear to have higher levels of IL-22 in
lavage samples compared with non-lung disease con-
trols. In patients with lung cancer, IL-22 levels in lavage
did not correlate with systemic signs of inflammation.
We found that within the lung, IL-22 may originate
from different cell populations.
The finding that patients with NSCLC show higher
levels of IL-22 in pulmonary lavage specimens is in line
with the results of a previous study reporting that lung
cancer cells may produce IL-22 [11]: Zhang and col-
leagues found high expression of IL-22 in primary
tumour tissue, serum, and malignant pleural effusion of
NSCLC patients, as well as expression of the IL-22 re-
ceptor (IL-22-R1) on lung cancer cell lines. We recently
studied the expression of IL-22 in tissue microarray
samples of a large cohort of lung cancer patients and
found IL-22 expression mostly in patients with large cell
NSCLC and those with small cell lung cancer 22 [12].
The lung cancer patient cohort in the present study is,
however, too small to confirm these histological sub-
group results. In the present study, we did not detect
IL-22 in BAL samples from some of the lung cancer
patients studied. While technical reasons may be put
forward to explain these results, levels of IL-22 may
vary significantly between tumor patients. Low levels
of IL-22 may be of prognostic relevance, as IL-22 is
thought to promote a more aggressive lung cancer
phenotype [12].
To the best of our knowledge, the present study is the
first to investigate IL-22 concentrations in pulmonary
lavage from cancer patients and show that IL-22 is ele-
vated in lavage samples from lung cancer patients. It
thus strengthens the hypothesis that IL-22 has a role in
lung cancer. The elevated IL-22 levels found in patients
with pulmonary manifestations of extrathoracic tumours
support the hypothesis that IL-22 may be a mediator in
cancer development and progression [18].
In addition to the data we have presented, IL-22
has been investigated in other non-malignant lung
diseases. A recent study in pulmonary lavage samples
from patients with bronchial asthma revealed that IL-
22 concentrations are elevated, further supporting
that IL-22 is a disease-associated cytokine detectable
in lavage and associated with lung inflammation, as
seen in our study [19]. Studies on the host response
towards bacterial or fungal pneumonia have revealed
that IL-22 contributes both to the acute phase, where
it supports clearance, and to the chronic phase,
where is prolongs inflammation. In chronic infections
such as tuberculosis, IL-22 seems to play a disease
promoting role [20]. Our study detected higher levels
of IL-22 in lavage samples from patients with pneu-
monia compared to controls, supporting the sugges-
tion that IL-22 plays a role in the pulmonary
response to infection. This is in line with previously
published data which identified IL-22 producing cells
in BAL from patients with pneumonia [21]. Recently,
IL-22 has been detected in lavage samples from pa-
tients with community-acquired pneumonia and cor-
related with serum levels of IL-22, corroborating our
finding that IL-22 is associated with pulmonary in-
flammation [21].
In the lung, IL-22 is thought to be mainly produced
by lymphoid cells, among others by CD4-positive
lymphocytes [5, 22, 23]. In previous studies analysing
lavage samples in patients with tuberculosis, T helper
cells were identified as the major source of IL-22 pro-
duction in BAL [22]. However, in our current study,
we did not find any association between IL-22 pro-
duction, and lymphocytes found in lavage from pa-
tients with pneumonia and the number of patients
with lung cancer was too low to draw firm conclu-
sions from the analysis with CD4 to CD8 T cell ratio.
While T cells as source of IL-22 in lung cancer have
not been proposed prior to our study, our data are
supported by evidence from other tumor types such
as colon, gastric or hepatic carcinomas where CD4 T
cells are thought to be the main sources of IL-22
[24–26]. In contrast, in lung cancer, the source of IL-
22 remains uncertain. One study has proposed that
IL-22 is expressed by the tumor cells themselves [11];
however, an earlier study from our group was not
able to confirm these results, supporting the notion
that IL-22 is expressed in the environment but not in
the tumor cells themselves [12]. This idea is pro-
moted by a recent study analysing IL-22 producing
cells in malignant pleural effusions which identified
CD4 T cells as major source [27]. Our study may
point towards a role for different cell populations ra-
ther than an individual one as source of IL-22 in the
lung, as we found no clear correlation between IL-22
and the analysed cell populations. However, the current
study was not powered to prove a lack of association be-
tween cell populations and IL-22 in the lung.
A noteworthy finding of the present study is the dis-
sociation between local IL-22 concentrations and sys-
temic parameters of inflammation such as CRP and
leukocyte counts in patients with lung cancer. This
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suggests that IL-22 in the lavage of lung cancer patients
reflects local processes in the lung rather than systemic
inflammation. The concept of the airway as a distinct
biological compartment with cytokine levels differing
from those in the systemic circulation is supported by
other studies: Hollander et al. [28] found that the
concentrations of IL-8 and of other markers of in-
flammation were significantly higher in BAL samples
compared to serum samples in patients with bron-
chial asthma and COPD.
Lavage is a clinically useful tool in the diagnostic
evaluation of many patients with pulmonary disease
and malignancy; however, clinicians must consider the
limitations of this technique when interpreting results.
The sensitivity of lavage cytology for lung cancer is
reported to be 48 %, lower than that of brushings or
endobronchial biopsy [29]. Biomarkers in lavage have
the potential to improve the sensitivity of this minimally
invasive method in lung cancer diagnosis. Techniques to
increase the concentration of IL-22 in lavage samples,
such as the use of small volume lavage or lavage
catheters placed near the tumor, may further increase
the diagnostic sensitivity.
Conclusion
IL-22 can be measured in lavage samples, and corre-
lates with the presence of lung disease. Lavage IL-22
concentrations are highest in patients with pneumonia
and lung cancer. IL-22 in lavage does not significantly
correlate with systemic inflammation. IL-22 concen-
trations were not significantly associated with a par-
ticular cell population found in the lavage, indicating
that IL-22 production may arise from different
sources. Our results suggest that IL-22 in pulmonary
lavage may serve as a marker for lung cancer, and,
perhaps, for pulmonary metastases of other tumours.
Markers expressed in the pulmonary compartment
can be sampled using bronchoscopic lavage, and may
mirror local disease states.
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